We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West’s Graham Reynolds will present “An Integrated Approach to Biologic Drug Delivery Systems: Meeting the needs of the patient, and optimizing drug product performance,” at the Drug Delivery Partnerships meeting in Las Vegas, on January 25, 2012.
Graham will speak at a session entitled “Maximize the potential of your drug delivery system through drug device combination products,” chaired by Phil Green, Senior Director Drug Delivery Devices at Merck.
The presentation will focus on the importance of considering four key elements of an integrated drug delivery system and the critical interfaces between them. These four elements are:
West is uniquely positioned to understand and support this need, combining leadership in drug containment systems with device development and manufacturing expertise, and a network of industry partnerships aimed at ensuring optimum packaging and delivery systems for today’s sophisticated drug products. Examples of solutions will be briefly discussed, including Daikyo Crystal Zenith® containment systems and the SmartDose® electronic patch injector, which is an ideal example of an integrated packaging and delivery system that meets a growing market need.
Graham Reynolds
VP & GM, Global Biologics
610 594 2935
Graham.Reynolds@westpharma.com
West markets SmartDose® as a multi-component system only. Final assembly of the prefilled component is completed by the pharmaceutical company. SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technology is licensed from Daikyo Seiko, Ltd.
In a previous <a href="/blog/2012/may/lifecycle-planning"><span style="text-decoration: underline;">post</span></a>, my colleague Fran DeGrazio discussed lifecycle planning and the use of a single material for packaging components from development through commercialization. There has been a great deal of innovation around drug container materials. Although glass has been the traditional material of choice for drug containment, it has significant limitations including breakage, glass particulate, visual quality and functional performance.
Join West’s Graham Reynolds as he presents the keynote at Pharmapack North America. Graham will present, “<em><strong>Understanding the regulations and safety concerns surrounding injectables to overcome inherent design challenges” </strong>on </em>Wednesday, May 23, 2012 at 1:50 pm. The conference will be held at the Pennsylvania Convention Center, Philadelphia, PA on May 22-23.
Polymeric container systems are not new to the pharmaceutical industry, and their benefits in terms of break resistance, cosmetic quality and dimensional precision have been recognized by many companies around the world who have chosen to use a polymer vial or syringe.
Combination products open up new vistas when it comes to delivering innovative therapies to patients in need, but teams bringing these products to the market face a number of significant hurdles. Recent surveys conducted by West at workshops held in PA and AZ have revealed some of our customers’ biggest challenges. This is the second of three blogs focused on these challenges — and how West can help Simplify the Journey™ when it comes to developing a combination product.
<span style="color: #000000;">West has completed a preliminary study of its SmartDose® technology platform, which incorporates a Daikyo Crystal Zenith® (CZ) cartridge. The study evaluated multiple attributes of the technology and subjects’ experience with the self-application process. </span>
English
Chinese
